OTC Healthcare in Uruguay
Euromonitor International's OTC Healthcare in Uruguay market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Buy online to access strategic market analysis and an interactive statistical database of volume and value market sizes, company and brand shares, distribution and pricing data.
Tables: 98 | Publication date: Jul 2008
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouth care; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; OTC triptans; Vitamins and dietary supplements; Wound treatments
Executive summary
Decline in prices slows growth
During 2007 the increasing competition seen in all OTC healthcare sectors, combined with the fall of the US dollar and the reduction of the VAT included in the tax reform, brought down prices, which in current terms remained in many instances at 2005 levels. Nevertheless, the strong performance in vitamins and dietary supplements helped to somewhat offset the slower growth or declines in value sales of more mature OTC healthcare products.
New health system raises doubts in pharmaceutical market
The implementation of the new Sistema Nacional Integrado de Salud (Integrated Nationwide Health System) involving both public and private health services and regulated by the Ministerio de Salud Pública (Public Health Ministry) includes the supply of medicines to the beneficiaries of the system. In public hospitals medicines will be either free of charge or acquired by paying a token fee. At private medical institutions, medicines will be available to patients as in the past, by paying a ticket for each remedy. As these private organisations fight to increase membership, they are lowering the cost of medicine tickets, often falling below the selling price of many of the medicines sold through regular distribution channels. Pharmaceuticals industry players and distributors are wary of how the market will evolve, and what percentage of medicine sales will be channelled through the nationwide health system.
Bayer SA maintains lead in fragmented market
The OTC healthcare market in Uruguay is quite fragmented, as with only a few exceptions all established pharmaceutical companies are active in this environment. Long-established Bayer SA maintains the overall lead in this fragmented environment, holding a value share of under 9% in 2007, based on consumers’ brand recognition. Domestic Laboratorio Spefar, which has the two best ranked products among the 300 best-selling remedies in the country, and fast growing Natural Life SA and Lukenor SA – both very strong in vitamins and dietary supplements – are slowly closing the gap with Bayer SA.
Government and industry back sales through pharmacies
The government is fighting contraband and illegal trade in every possible area, and through the Ministerio de Salud Pública it campaigns against buying medicines outside legally established channels. This campaign is mainly aimed at limiting purchases via street markets of medicines of dubious origin (mostly stolen from public hospitals or smuggled into Uruguay from neighbouring countries). The ministry stresses both the need for a doctor’s prescription and to obtain the medicines from pharmacies, avoiding other sources. The industry also favours this approach: most notable is Roemmers’ institutional campaign in this respect, which has been run for several years.
Growth predicted to accelerate in coming years
It is expected that prices will tend to stabilise and start to recover during the early years of the forecast period, as companies adjust to the new health system, absorb the effects of the tax reform and realise that competing only by reducing prices can not be maintained for long, and has a limit which can not be surpassed. Consumer demand is growing in volume terms in the largest product types, and increasing concerns regarding healthier lifestyles should continue to fuel the rapid growth of vitamins and dietary supplements. The combined effect of volume growth and more reasonable price policies should stimulate retail value growth in most niches, with a few exceptions, where specific remedies are being replaced by new products from other categories. Some examples include proton pump inhibitors replacing H2 blockers and ibuprofen replacing other analgesics like diclofenac and dipyrone.
Table of contents
OTC HEALTHCARE IN URUGUAY : MARKET INSIGHT
EXECUTIVE SUMMARY
Decline in prices slows growth
New health system raises doubts in pharmaceutical market
Bayer SA maintains lead in fragmented market
Government and industry back sales through pharmacies
Growth predicted to accelerate in coming years
MARKET INDICATORS
Table 1 Life Expectancy at Birth 2002-2007
MARKET DATA
Table 2 Sales of OTC Healthcare by Sector: Value 2002-2007
Table 3 Sales of OTC Healthcare by Sector: % Value Growth 2002-2007
Table 4 OTC Healthcare Company Shares by Value 2003-2007
Table 5 OTC Healthcare Brand Shares by Value 2004-2007
Table 6 Sales of OTC Healthcare by Distribution Format: % Analysis 2002-2007
Table 7 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2007
Table 8 Forecast Sales of OTC Healthcare by Sector: Value 2007-2012
Table 9 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2007-2012
APPENDIX
OTC Registration and Classification
Vitamins & Dietary Supplements Registration and Classification
Generics
Switches
DEFINITIONS
Sources
Summary 1 Research Sources
ANALGESICS
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 10 Sales of Analgesics by Subsector: Value 2002-2007
Table 11 Sales of Analgesics by Subsector: % Value Growth 2002-2007
Table 12 Analgesics Company Shares by Value 2003-2007
Table 13 Analgesics Brand Shares by Value 2004-2007
Table 14 Forecast Sales of Analgesics by Subsector: Value 2007-2012
Table 15 Forecast Sales of Analgesics by Subsector: % Value Growth 2007-2012
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 16 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2002-2007
Table 17 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2002-2007
Table 18 Sales of Decongestants by Type: Value 2002-2007
Table 19 Sales of Decongestants by Type: % Value Growth 2002-2007
Table 20 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: Value 2002-2007
Table 21 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: % Value Growth 2002-2007
Table 22 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2003-2007
Table 23 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2004-2007
Table 24 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2007-2012
Table 25 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2007-2012
DIGESTIVE REMEDIES
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 26 Sales of Digestive Remedies by Subsector: Value 2002-2007
Table 27 Sales of Digestive Remedies by Subsector: % Value Growth 2002-2007
Table 28 Digestive Remedies Company Shares by Value 2003-2007
Table 29 Digestive Remedies Brand Shares by Value 2004-2007
Table 30 Forecast Sales of Digestive Remedies by Subsector: Value 2007-2012
Table 31 Forecast Sales of Digestive Remedies by Subsector: % Value Growth 2007-2012
MEDICATED SKIN CARE
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 32 Sales of Medicated Skin Care by Subsector: Value 2002-2007
Table 33 Sales of Medicated Skin Care by Subsector: % Value Growth 2002-2007
Table 34 Medicated Skin Care Company Shares by Value 2003-2007
Table 35 Medicated Skin Care Brand Shares by Value 2004-2007
Table 36 Hair Loss Treatments Brand Shares by Value 2004-2007
Table 37 Forecast Sales of Medicated Skin Care by Subsector: Value 2007-2012
Table 38 Forecast Sales of Medicated Skin Care by Subsector: % Value Growth 2007-2012
VITAMINS AND DIETARY SUPPLEMENTS
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 39 Sales of Vitamins and Dietary Supplements by Subsector: Value 2002-2007
Table 40 Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2002-2007
Table 41 Sales of Vitamins by Type: Value 2002-2007
Table 42 Sales of Vitamins by Type: % Value Growth 2002-2007
Table 43 Sales of Dietary Supplements by Type: Value 2002-2007
Table 44 Sales of Dietary Supplements by Type: % Value Growth 2002-2007
Table 45 Vitamins and Dietary Supplements Company Shares by Value 2003-2007
Table 46 Vitamins and Dietary Supplements Brand Shares by Value 2004-2007
Table 47 Vitamins Brand Shares by Value 2004-2007
Table 48 Dietary Supplements Brand Shares by Value 2004-2007
Table 49 Forecast Sales of Vitamins and Dietary Supplements by Subsector: Value 2007-2012
Table 50 Forecast Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2007-2012
NRT SMOKING CESSATION AIDS
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Table 51 Sales of Smoking Cessation Aids by Subsector: Value 2002-2007
Table 52 Sales of Smoking Cessation Aids by Subsector: % Value Growth 2002-2007
Table 53 Smoking Cessation Aids Company Shares by Value 2003-2007
Table 54 Smoking Cessation Aids Brand Shares by Value 2004-2007
Table 55 Forecast Sales of Smoking Cessation Aids by Subsector: Value 2007-2012
Table 56 Forecast Sales of Smoking Cessation Aids by Subsector: % Value Growth 2007-2012
EYE CARE
Sector Data
Table 57 Sales of Eye Care by Subsector: Value 2002-2007
Table 58 Sales of Eye Care by Subsector: % Value Growth 2002-2007
Table 59 Eye Care Company Shares by Value 2003-2007
Table 60 Eye Care Brand Shares by Value 2004-2007
Table 61 Forecast Sales of Eye Care by Subsector: Value 2007-2012
Table 62 Forecast Sales of Eye Care by Subsector: % Value Growth 2007-2012
WOUND TREATMENTS
Sector Data
Table 63 Sales of Wound Treatments by Subsector: Value 2002-2007
Table 64 Sales of Wound Treatments by Subsector: % Value Growth 2002-2007
Table 65 Wound Treatments Company Shares by Value 2003-2007
Table 66 Wound Treatments Brand Shares by Value 2004-2007
Table 67 Forecast Sales of Wound Treatments by Subsector: Value 2007-2012
Table 68 Forecast Sales of Wound Treatments by Subsector: % Value Growth 2007-2012
EAR CARE
Sector Data
Table 69 Sales of Ear Care: Value 2002-2007
Table 70 Sales of Ear Care: % Value Growth 2002-2007
Table 71 Ear Care Company Shares by Value 2003-2007
Table 72 Ear Care Brand Shares by Value 2004-2007
Table 73 Forecast Sales of Ear Care: Value 2007-2012
Table 74 Forecast Sales of Ear Care: % Value Growth 2007-2012
ADULT MOUTH CARE
Sector Data
Table 75 Sales of Adult Mouth Care: Value 2002-2007
Table 76 Sales of Adult Mouth Care: % Value Growth 2002-2007
Table 77 Adult Mouth Care Company Shares by Value 2003-2007
Table 78 Adult Mouth Care Brand Shares by Value 2004-2007
Table 79 Forecast Sales of Adult Mouth Care: Value 2007-2012
Table 80 Forecast Sales of Adult Mouth Care: % Value Growth 2007-2012
CALMING AND SLEEPING PRODUCTS
Sector Data
Table 81 Sales of Calming and Sleeping Products: Value 2002-2007
Table 82 Sales of Calming and Sleeping Products: % Value Growth 2002-2007
Table 83 Calming and Sleeping Products Company Shares by Value 2003-2007
Table 84 Calming and Sleeping Products Brand Shares by Value 2004-2007
Table 85 Forecast Sales of Calming and Sleeping Products: Value 2007-2012
Table 86 Forecast Sales of Calming and Sleeping Products: % Value Growth 2007-2012
EMERGENCY CONTRACEPTION
Sector Data
Table 87 Sales of Emergency Contraception: Value 2002-2007
Table 88 Sales of Emergency Contraception: % Value Growth 2002-2007
Table 89 Forecast Sales of Emergency Contraception: Value 2007-2012
Table 90 Forecast Sales of Emergency Contraception: % Value Growth 2007-2012
LABORATORIO LIBRA SA
Strategic Direction
Key Facts
Summary 2 Laboratorio Libra SA: Key Facts
Company Background
ProduCtion
Competitive Positioning
Summary 3 Laboratorios Libra SA: Competitive Position 2007
LABORATORIO LAZAR SA
Strategic Direction
Key Facts
Summary 4 Laboratorio Lazar SA: Key Facts
Company Background
Production
Competitive Positioning
Summary 5 Laboratorio Lazar SA: Competitive Position 2007
DERMUR LTDA
Strategic Direction
Key Facts
Summary 6 Dermur Ltda: Key Facts
Summary 7 Dermur Ltda: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 8 Dermur Ltda: Competitive Position 2007